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Abstract
The study of miRNAs and other noncoding RNAs has revolutionised our understanding of gene expression
regulation during cancer development and progression, creating one of the fastest-growing research fields in
cancer with realistic therapeutic potential. The 2011 Non-coding RNAs and Cancer Symposium hosted by the
University College London Cancer Institute focused on the function and regulation of noncoding RNAs during
oncogenesis.
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Introduction
Understanding the mechanisms that regulate gene
expression during cancer development is of paramount
importance for the development of effective therapeutic
regimens. The discovery of miRNAs, a class of noncod-
ing RNA genes with a role in gene silencing [1-3],
caused a dramatic increase in research activity aimed at
unravelling the role of noncoding RNAs in cancer. It
has now become apparent that it is necessary to study
the function of miRNAs and other noncoding RNAs,
which account for almost 40% of the human genome
[4], and integrate these findings with our understanding
of the functions of protein-coding genes, which compose
almost 2% of the human genome, in cancer. During the
2011 Non-coding RNAs and Cancer Symposium in Lon-
don, some fascinating aspects of the role of noncoding
RNAs in cancer were discussed.
miRNAs as oncogenes and tumour suppressors
miRNAs are a class of small noncoding RNAs, approxi-
mately 22 nucleotides long, that are involved in post-
transcriptional gene regulation. They arise from
intergenic or intragenic genomic regions and are tran-
scribed as long primary transcripts. These primary tran-
scripts undergo two processing steps that produce the
mature form of the miRNA. Once processed, miRNAs
are loaded into the RNA-induced silencing complex
(RISC), directing it to target mRNAs and causing
posttranscriptional repression [5,6]. The discovery of
miRNAs has led to profound changes in the understand-
ing of eukaryotic gene-regulatory networks. Functional
studies indicate that miRNAs participate in the regula-
tion of almost every cellular process examined, and
changes in their expression characterise several human
diseases, including cancer. miRNAs constitute about 3%
to 5% of predicted genes in the human genome, and
about one-fourth of protein-coding genes are estimated
to be regulated by them [7]. A growing amount of evi-
d e n c ep r o v e st h a tm i R N A sc a nw o r ka so n c o g e n e sb y
activating the malignant potential of cells or, conversely,
as tumour suppressor genes by blocking this potential
[5,8]. However, since specific miRNAs can regulate dif-
ferent targets in different tissues, one cannot describe
them as tumour suppressors or oncogenes before speci-
fying the tissue of their action [8].
One of the first lines of evidence that miRNAs can act
as oncogenes or tumour suppressors came from the dis-
c o v e r yo ft h er o l eo fm i R - 1 6 - 1a n dm i R - 1 5 ai nc h r o n i c
lymphocytic leukaemia (CLL), as presented by Carlo M
Croce (Human Cancer Genetics Program, The Ohio
State University Medical Center, Columbus, OH, USA).
During attempts to clone a tumour suppressor gene at
13q14, a chromosomal region that is frequently lost in
CLL, the CLL suppressor gene was found to be located
in a small genomic region in which there are no pro-
tein-coding genes. However, two miRNA genes, miR-
15a and miR-16-1, are located within this region. This
indicates that miR-15a and miR-16-1 can function as
tumour suppressors and that their loss is associated
with the development of the indolent form of CLL [9].
Following this discovery, Croce and colleagues mapped
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and surprisingly, they found that many miRNA genes
are located within regions that are frequently altered in
many types of human cancer [10]. In the case of miR-
16-1 and miR-15a in CLL, the two miRNAs act as
tumour suppressors by suppressing expression of BCL2,
an oncogene that inhibits apoptosis and whose overex-
pression appears to be a crucial event during the initia-
tion of most forms of the disease [11,12].
On the other hand, miR-155 is overexpressed in aggres-
sive CLL and acts as an oncogene in CLL [13]. It has been
suggested that miR-155 enhances the mutation rate of
CLL by targeting genes involved in DNA repair and cell
cycle regulation [14,15]. Moreover, transgenic mice with
targeted overexpression of miR-155 in B cells developed a
polyclonal expansion of large pre-B cells followed by leu-
kaemia or high-grade lymphoma, demonstrating that a
miRNA can contribute directly to the pathogenesis of
malignancy [16]. These results indicate that the dysregula-
tion of a single miRNA can lead to the development of a
malignant tumour. Following the above-described seminal
discoveries, several miRNAs have been shown to act as
tumour suppressors or oncogenes [8].
miRNAs in tissue development and degeneration
miRNAs have been shown to play a central role in can-
cer angiogenesis [17,18]. The study of miRNAs during
normal vascular development in vivo has provided useful
insight into miRNA function in pathological angiogen-
esis. To this purpose, the use of zebrafish provides an
ideal model for uncovering the contribution of indivi-
dual miRNAs in development. Using this approach,
Antonio Giraldez and colleagues (Department of Genet-
ics, Yale University, New Haven, CT, USA) described
the identification of 245 mRNAs that are posttranscrip-
tionally regulated by muscle miRNAs in zebrafish. Two
muscle-specific miRNAs, miR-1 and miR-133, appear to
instruct embryonic muscle gene expression and to
downregulate specific targets in muscle. They also iden-
tified a set of targets with relatively low expression in
muscle tissue whose downregulation is miRNA-indepen-
dent. This led them to suggest that there are two modes
of gene regulation in muscle cells: the first is governed
by miRNAs, and the second is primarily regulated at the
transcriptional level with miRNAs acting only to fine-
tune expression level. Furthermore, they found a num-
ber of actin-related and actin-binding proteins among
the miR-1 and miR-133 targets, suggesting that these
miRNAs regulate sarcomeric actin organization [19].
Intriguingly, the group also found that some muscle-
specific miRNAs may also play a role in angiogenesis
during zebrafish development.
Interestingly, the involvement of miRNAs in cell pro-
liferation and function is also demonstrated through
studies of other diseases, such as neurodegenerative
conditions. In this respect, Eran Hornstein (The Weiz-
mann Institute of Science, Rehovot, Israel) presented a
model for spinal motor neuron (SMN) disease that is
based on loss of Dicer1 function. It is already well estab-
lished that posttranscriptional gene regulation plays a
crucial role in the development and function of neurons,
and alterations in miRNA function have been found to
contribute to neuronal disease susceptibility. In addition,
several RNA-binding proteins involved in the miRNA
biogenesis pathway were also found to be mutated in
neuronal diseases such as amyotrophic lateral sclerosis
(ALS). Deep sequencing was used to investigate the neu-
ronal miRNA milieu, which was found to be dominated
by four miRNAs: both arms of miR-9, Hoxmir and let-7.
To explore the involvement of miRNAs in the patho-
genesis of motor neuron (MN) disease, an MN Dicer-
mutant mouse was created. These mice have denerva-
tion muscular atrophy, which suggests loss of SMNs,
and exhibit a significant decrease in MN axon numbers.
It has previously been shown that the coordinated
expression levels of the neurofilament subunit proteins
are disturbed in human ALS, which can be caused by
upregulation of the heavy subunit. Hornstein’sg r o u p
[20] suggested that miR-9 coordinates the expression of
the neurofilament subunits by regulating the expression
of the heavy subunit. This hypothesis was reinforced
when they found that miR-9 is also specifically downre-
gulated in other models of MN disease.
miRNAs and epigenetic switches
Kevin Struhl (Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical School, Bos-
ton, MA, USA) described a link between miRNAs and
epigenetic changes that occur in an inducible model of
cellular transformation. In this model, nontransformed
mammary epithelial cell lines containing oestrogen
receptor and Src are treated with tamoxifen. This treat-
ment rapidly induces Src, and morphological transfor-
mation is observed within 36 hours. Src activation
triggers an inflammatory response that results in an epi-
genetic switch between nontransformed and trans-
formed cells. The epigenetic switch is mediated by a
positive feedback loop involving NF-B, Lin28b, let-7
and IL-6 [21]. This regulatory circuit is not exclusive to
this model and operates in other cancer cell lines, and
its transcriptional signature is found in patient cancer
tissues. They used this model to look for miRNAs, the
expression of which is changed during the course of
transformation. Intriguingly, they found two miRNAs,
miR-21 and miR-181b-1, that not only are overex-
pressed during transformation, but transient expression
of either of them is sufficient to induce a stable trans-
formed state. This suggests that these miRNAs are part
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their expression is regulated by IL-6 and that both miR-
21 and miR-181b-1 can activate NF-B by targeting and
inhibiting the tumour suppressors PTEN and CYLD
[22].
The Croce group also found that miRNAs regulate
epigenetic changes. An example is the miR-29 family,
which is downregulated in acute leukaemias and targets
(directly and indirectly) several DNA methyltransferases.
Introduction of the miR-29 family into lung cancer cell
lines caused demethylation of the CpG islands in the
promoter regions of tumour suppressor genes, which
allowed their reactivation and resulted in loss of
tumourigenicity [23,24].
Making sense of the mess
miRNAs bind their target mRNAs through base pairing,
which occurs primarily between positions 2 and 8 of the
mature miRNA and sequences in the 3’UTR of the tar-
get mRNA [6]. Because of the nature of this molecular
targeting mechanism, one of the biggest challenges in
the field of miRNAs is distinguishing biologically rele-
vant miRNA-mRNA interactions. Until recently, identifi-
cation of miRNA target sites predominantly relied on
computational methods that are limited in their ability
to predict specific and physiologically relevant targets
[25]. Lately several studies have addressed this problem
by utilising immunoprecipitation of miRNA effector
complexes consisting of one of the Argonaute proteins
(the central protein component of RISC) cross-linked
with associated miRNAs and mRNAs. This cross-linking
and immunoprecipitation (CLIP), coupled with deep
sequencing, provides transcriptome-wide coverage as
well as high resolution. However, partly because it is so
vast, the data that have so far been generated in CLIP
experiments have not yet been put in a form that
enables fast and interactive exploration of binding sites.
Mihaela Zavolan (The Center for Molecular Life
Sciences, University of Basel, Basel, Switzerland) pre-
sented a new database named CLIPZ that was developed
for this purpose. This is a database of binding sites that
were constructed based on CLIP data for various RNA-
binding proteins (RBPs), which are known to regulate
mRNA splicing, stability and/or translation rate [26].
The increasing arsenals of noncoding RNAs
Although miRNAs are the most frequently studied
RNAs, they comprise only a small portion of the cellular
noncoding RNA. The development of deep sequencing
technologies and the improved analysis tools have
allowed the identification of new groups of small non-
coding RNA. In his talk, Gyorgy Hutvagner (Wellcome
Trust Centre, Dundee, UK) described how, by a combi-
nation of in silico analysis with in vivo and in vitro
experiments, his research group was able to identify a
new group of small RNAs, which are generated after
processing of mature or precursor transfer RNAs
(tRNAs). This process gives rise to two types of tRNA-
derived RNA fragments (tRFs), 5’tRFs and 3’tRFs, pro-
duced from the 5’ and 3’ ends of the tRNA, respectively.
Moreover, the formation of these tRFs is dependent on
Dicer activity [27].
Richard Jenner (Department of Infection and Immu-
nity, University College London, London, UK) presented
another new class of short RNAs that are transcribed
from the 5’ end of polycomb target genes. Polycomb
group proteins are essential for embryogenesis and for
maintaining embryonic stem (ES) cells’ pluripotency and
differentiated states. PRC2 is a polycomb repressive
complex that catalyses the trimethylation of lysine 27 of
histone H3, forming a binding site for PRC1. This
enables the repression of hundreds of developmental
regulators in ES cells that would otherwise induce cell
differentiation. Although repressed, PCR2 target genes
are associated with histone H3K4me3, a marker of tran-
scription initiation. In addition, it has been shown that
PRC2 can interact with long noncoding RNA transcripts
such as RepA or HOTAIR. In the course of the Jenner
group’s work, they identified a new class of short RNAs,
50 to 200 nucleotides long that are transcribed from the
5’ end of polycomb target genes. These short RNAs
interact with PRC2 through a stem-loop structure and
cause gene repression in cis. During cell differentiation,
these RNAs are depleted from the polycomb targets.
This new model can explain why polycomb target genes
are associated with transcriptional activation markers
and provides a potential new role for small RNAs in the
interaction of PRC2 with its target genes [28].
RNA-protein interactions in cancer
Posttranslational regulation through interaction between
mRNAs and RBPs occurs in a small RNA-dependent or
-independent manner. Examples of small RNA-depen-
dent interactions include the above-mentioned gene
expression suppression by RISC or PRC. Martin Turner
(Babraham Institute, Cambridge, UK) presented findings
highlighting the function of RBPs in T-lymphocytes and
leukaemia. TIS11b and TIS11d are RBPs that interact
with AU-rich elements in the 3’UTR of mRNA, which
leads to mRNA degradation and translational repression.
Turner’s research group has shown that mice lacking
these proteins during thymopoiesis develop T-cell acute
lymphoblastic leukaemia (T-ALL). They found that
these RBPs bind to the 3’UTR of the transcription factor
Notch1 and by doing so, suppress its expression. The
absence of these two RBPs leads to higher expression of
Notch1, which can cause perturbation and higher meta-
bolic activity. Finally, developing T-ALL in their model
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Indeed, these proteins are dysregulated in several differ-
ent types of cancer. These results demonstrate the criti-
cal role of RBPs in thymocyte development and in the
prevention of transformation [29].
miRNAs as therapeutics
miRNAs play an important role in many different disor-
ders, particularly in cancer, where they have been shown
to act as both tumour suppressors and oncogenes. They
have also been shown to function in viral defence and
can prevent viral infection. Sakari Kauppinen (Santaris
Pharma A/S, Hørsholm, Denmark) presented a new
approach that enables miRNA antagonism using tiny,
locked nucleic acids (tiny LNAs). These are fully modi-
fied phosphorothionate oligonucleotides, which are com-
plementary to the miRNA seed region. Since miRNA
families share the same seed sequence, the great advan-
tage of tiny LNAs is that a single molecule is able to
repress an entire miRNA family, as shown for the let-7
family. More importantly, they demonstrated that sys-
tematically delivered, unconjugated tiny LNAs showed
uptake into many normal tissues and into breast
tumours in mice, which coincided with long-term
miRNA silencing. Using a specific LNA, they were able
to inhibit miR-21,ak n o w nm i R N Ao n c o g e n e ,b o t hin
vitro and in vivo, and prevent its oncogenic effect [30].
LNA-mediated miRNA antagonism is also used for
prevention of viral infection in the most advanced clinical
trial targeting a miRNA http://www.santaris.com/pro-
duct-pipeline. miR-122 binds to two closely spaced target
sites in the 5’ noncoding region of the hepatitis C virus
(HCV) genome, resulting in upregulation of viral RNA
levels. Interaction of miR-122 with the HCV genome is
essential for accumulation of viral RNA in cultured liver
cells. Treatment of chronically infected chimpanzees with
a LNA complementary to miR-122 leads to long-lasting
suppression of HCV viraemia with no evidence of viral
resistance [31]. Following these studies in preclinical
models, and after successful completion of phase I clini-
cal trials of these compounds in humans, the phase II
trial is now ongoing for treatment of HCV.
A noncoding RNA world
Individual miRNAs have multiple targets, which in prin-
ciple can compete against each other for binding to the
miRNA. Therefore, one can assume that an independent
change in the expression of one RNA in this network will
affect the levels of all the rest. This network can include
not only mRNAs but also noncoding RNAs such as pseu-
dogenes. This theory expands on the central dogma,
since it means that a gene does not have to be translated
to have a function. This hypothesis was first suggested by
Pier-Paolo Pandolfi and was termed ‘the ceRNA hypoth-
esis’. Dr Pandolfi (Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, USA) described
the function of gene and pseudogene mRNAs in tumour
biology as a model for the protein coding-independent
role of RNAs. In this work, they tested the relationship
between PTEN and its pseudogene PTEN1. PTEN is
downregulated in 70% of human cancers, and there are
several indications that it functions as a haploinsufficient
tumour suppressor gene [32]. PTEN expression is down-
regulated by several different miRNAs, and it was
demonstrated that posttranscriptional regulation has a
pivotal role in determining PTEN abundance in cancer
cells. The pseudogene PTEN1 is conserved, and its
3’UTR includes miRNA recognition elements shared
with the PTEN 3’UTR. In their work, Pandolfi and collea-
gues found that the pseudogene PTEN1 is biologically
active, as it regulates PTEN expression by sequestering
shared miRNAs, preventing them from binding to the
3’UTR of PTEN. They found that expression of the
PTEN1 3’UTR alone was sufficient to cause overexpres-
sion of PTEN and prevent tumourigenesis. They also
found that the PTEN1 locus is selectively lost in human
cancers. These results suggest that PTEN1, despite its not
coding for a protein, can act as a tumour suppressor
gene. These findings point towards a new layer of com-
plexity in the field of the noncoding RNAs and their role
in posttranscriptional regulation. According to this
model, when identifying the miRNA recognition ele-
ments in a specific gene, it will also be necessary to look
for these elements in other genes. This will allow the elu-
cidation of the full network of noncoding RNAs that reg-
ulate expression of a particular gene [32].
Conclusions
The 2011 Non-coding RNAs and Cancer Symposium
highlighted the role of miRNAs and other noncoding
RNAs as crucial molecular switches in cancer. During
the meeting, it emerged that there are still exciting chal-
lenges in understanding the function and regulation of
the various noncoding RNA classes in cancer. These
challenges include the accurate and unbiased identifica-
tion of miRNA targets, the elucidation of the role of
novel classes of noncoding RNAs in cancer (such as
tRFs and polycomb-associated RNAs) and the in-depth
investigation of direct interactions between noncoding
RNAs and their relevance to cancer biology. However, it
also became apparent that the use of noncoding RNA-
based therapeutics and diagnostics in cancer medicine is
fast approaching.
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